Drug Profile
Anti CD34 monoclonal antibody/sirolimus - OrbusNeich
Alternative Names: Combo Dual Therapy Stent; COMBO Plus Dual Therapy Stent; OrbusNeich Combo Stent™Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator OrbusNeich
- Class Anti-infectives; Ischaemic heart disorder therapies; Macrolides; Monoclonal antibodies
- Mechanism of Action MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Coronary artery restenosis
- No development reported Coronary artery disease
Most Recent Events
- 10 Jun 2021 OrbusNeich completes the RECOVERY trial in Coronary artery disease in China (Intracoronary) (NCT02542007)
- 26 Sep 2019 Registered for Coronary artery restenosis (Prevention) in Japan (Intracoronary)
- 25 Oct 2018 Phase-II/III HARMONEE registrational trial is ongoing in Japan and USA (NCT02073565)